TABLE OF CONTENTS
Volume 22, Issue 11 (November 2008)
Spotlight Reviews |
Review |
Original Articles |
Letters to the Editor |
Corrigendum
Spotlight Editorial
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
N C P Cross, G Q Daley, A R Green, T P Hughes, C Jamieson, P Manley, T Mughal, D Perrotti, J Radich, R Skoda, S Soverini, W Vainchenker, S Verstovsek, J-L Villeval and J M Goldman
Leukemia 22: 1975-1989; doi:10.1038/leu.2008.231
Spotlight Reviews
Interferon-
therapy in bcr-abl-negative myeloproliferative neoplasms FREE
J-J Kiladjian, C Chomienne and P Fenaux
Leukemia 22: 1990-1998; advance online publication, October 9, 2008; doi:10.1038/leu.2008.280
Five years since the discovery of FIP1L1–PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias FREE
J Gotlib and J Cools
Leukemia 22: 1999-2010; advance online publication, October 9, 2008; doi:10.1038/leu.2008.287
Miscreant myeloproliferative disorder stem cells
C H M Jamieson, C F Barroga and W P Vainchenker
Leukemia 22: 2011-2019; advance online publication, October 16, 2008; doi:10.1038/leu.2008.290
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation FREE
R Landolfi, L Di Gennaro and A Falanga
Leukemia 22: 2020-2028; advance online publication, September 18, 2008; doi:10.1038/leu.2008.253
Review
Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia
J A Kennedy and F Barabé
Leukemia 22: 2029-2040; advance online publication, August 7, 2008; doi:10.1038/leu.2008.206
Original Articles
Acute Leukemias
HOX expression patterns identify a common signature for favorable AML
M Andreeff, V Ruvolo, S Gadgil, C Zeng, K Coombes, W Chen, S Kornblau, A E Barón and H A Drabkin
Leukemia 22: 2041-2047; advance online publication, July 31, 2008; doi:10.1038/leu.2008.198
Chronic Lymphocytic Leukemia
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
J E Castro, J D Sandoval-Sus, J Bole, L Rassenti and T J Kipps
Leukemia 22: 2048-2053; advance online publication, August 28, 2008; doi:10.1038/leu.2008.214
Stem Cells
Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis
I Müller, M Vaegler, C Holzwarth, N Tzaribatchev, S M Pfister, B Schütt, P Reize, J Greil, R Handgretinger and M Rudert
Leukemia 22: 2054-2061; advance online publication, August 21, 2008; doi:10.1038/leu.2008.217
Impact of comorbidity indexes on non-relapse mortality
A Xhaard, R Porcher, J W Chien, R P de Latour, M Robin, P Ribaud, V Rocha, A Devergie, C Ferry, P J Martin and G Socié
Leukemia 22: 2062-2069; advance online publication, August 7, 2008; doi:10.1038/leu.2008.197
Immunology
Ex vivo priming of CD4 T cells converts immunological tolerance into effective antitumor immunity in a murine model of acute lymphoblastic leukemia
A N Hegazy and C Klein
Leukemia 22: 2070-2079; advance online publication, July 17, 2008; doi:10.1038/leu.2008.193
Sensitivity and Resistance to Therapy
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
J A McCubrey, S L Abrams, G Ligresti, N Misaghian, E W T Wong, L S Steelman, J Bäsecke, J Troppmair, M Libra, F Nicoletti, S Molton, M McMahon, C Evangelisti and A M Martelli
Leukemia 22: 2080-2090; advance online publication, August 7, 2008; doi:10.1038/leu.2008.207
Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis
L Gu, J Gao, Q Li, Y P Zhu, C S Jia, R Y Fu, Y Chen, Q K Liao and Z Ma
Leukemia 22: 2091-2096; advance online publication, August 7, 2008; doi:10.1038/leu.2008.204
Lymphoma
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2
M Klier, N Anastasov, A Hermann, T Meindl, D Angermeier, M Raffeld, F Fend and L Quintanilla-Martinez
Leukemia 22: 2097-2105; advance online publication, August 7, 2008; doi:10.1038/leu.2008.213
Letters to the Editor
STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma
O Ritz, C Guiter, K Dorsch, I Dusanter-Fourt, S Wegener, H Jouault, P Gaulard, F Castellano, P Möller and K Leroy
Leukemia 22: 2106-2110; advance online publication, April 10, 2008; doi:10.1038/leu.2008.85
Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia
M Burcu, K L O'Loughlin, L A Ford and M R Baer
Leukemia 22: 2110-2115; advance online publication, April 17, 2008; doi:10.1038/leu.2008.87
In-vivo detectable antibodies directed against the oncofetal antigen/immature laminin receptor can recognize and control myeloma cells—clinical implications
S Siegel, B Friedrichs, A-K Budde, A Barsoum, J Coggin Jr, M Tiemann, D Kabelitz and M Zeis
Leukemia 22: 2115-2118; advance online publication, May 1, 2008; doi:10.1038/leu.2008.92
The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group
J Schwarz, M Penka, K Indrák, D Pospí
ilová, R Pytlík, P Dulí
ek, M Doubek, L K
en and V Campr on behalf of the Czech MPD Working Group
Leukemia 22: 2118-2119; advance online publication, April 17, 2008; doi:10.1038/leu.2008.93
Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors
B Mazzi, T D Clerici, M Zanussi, M T Lupo Stanghellini, L Vago, E Sironi, J Peccatori, M Bernardi, P Carrera, A Palini, S Rossini, C Bordignon, C Bonini, M Ferrari, F Ciceri and K Fleischhauer
Leukemia 22: 2119-2122; advance online publication, May 1, 2008; doi:10.1038/leu.2008.98
The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia
E Chapiro, I Radford-Weiss, C Bastard, I Luquet, C Lefebvre, E Callet-Bauchu, D Leroux, P Talmant, M-J Mozziconacci, F Mugneret, S Struski, S Raynaud, J Andrieux, C Barin, M Jotterand, H Mossafa, S Ramond, C Terré, E Lippert, F Berger, P Felman, H Merle-Béral, O A Bernard, F Davi, R Berger and F Nguyen-Khac on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH)
Leukemia 22: 2123-2127; advance online publication, May 1, 2008; doi:10.1038/leu.2008.102
Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia
G Caocci, S Atzeni, N Orrù, L Azzena, L Martorana, R Littera, A Ledda and G La Nasa
Leukemia 22: 2127-2128; advance online publication, May 8, 2008; doi:10.1038/leu.2008.106
Association of KIR2DS4 and its variant KIR1D with leukemia
S Giebel, I Nowak, J Wojnar, M Krawczyk-Kulis, J Holowiecki, S Kyrcz-Krzemien and P Kusnierczyk
Leukemia 22: 2129-2130; advance online publication, May 8, 2008; doi:10.1038/leu.2008.108
Reply to: Association of KIR2DS4 and its variant KIR1D with leukemia
S Verheyden and C Demanet
Leukemia 22: 2130-2131; advance online publication, May 8, 2008; doi:10.1038/leu.2008.109
Reply to Verheyden and Demanet
S Giebel, I Nowak, E Majorczyk and P Kusnierczyk
Leukemia 22: 2131; doi:10.1038/leu.2008.110
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization
M G Berger, J Berger, C Richard, S Jeanpierre, F E Nicolini, O Tournilhac, M Michallet and V M Satta
Leukemia 22: 2131-2134; advance online publication, July 3, 2008; doi:10.1038/leu.2008.167
Corrigendum
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization FREE
M G Berger, J Berger, C Richard, S Jeanpierre, F E Nicolini, O Tournilhac, M Michallet and V Maguer-Satta
Leukemia 22: 2135; doi:10.1038/leu.2008.202
